---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-117243"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:52:59.860603+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics Q3 net loss $9.9M; CT1812 slows decline 95% in Alzheimer's sub-group

## Summary
- Net loss $9.9M ($0.25/share) vs $6.7M ($0.22/share) in Q3 2023; cash $22M plus $53.6M NIA grants.
- CT1812 showed 95% slowing of cognitive decline (ADAS-Cog11) in Alzheimer's patients with low p-tau217 at CTAD.
- On track to report Phase 2 SHIMMER topline results in dementia with Lewy bodies by end of 2024.
- Plans to request end-of-Phase 2 FDA meeting for CT1812 Alzheimer's program.
- Cash runway into Q2 2025; R&D expense $11.4M, G&A $3.1M both flat YoY.

## SEC filing metadata
- accession: 0001104659-24-117243
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465924117243/0001104659-24-117243-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465924117243/tm2428074d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-117243
- JSON: https://secwatch.observer/filing/0001104659-24-117243.json
- Plain text: https://secwatch.observer/filing/0001104659-24-117243.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.